Clinical trials: CTLA-4
NSCLC Stage IV, NSCLC Stage IIIB
Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)
This phase Ib/II trial studies how well cadonilimab combined with anlotinib and docetaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back.
- Conditions
- NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC
- Trial name
- AK104IIT018 (NCT05816499)
- Testing
- Cadonilimab, Anlotinib, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Tumors
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
- Trial name
- NCT05235542
- Testing
- AK104, AK117, Capecitabine tablets
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Akeso
Hepatocellular Carcinoma
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
- Trial name
- NCT06280105
- Testing
- Cadonilimab+regorafenib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Meng Chao Hepatobiliary Hospital of Fujian Medical University
Takayasu's Arteritis, Giant Cell Arteritis
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms.
- Trial name
- NCT00556439
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NSCLC Stage II, NSCLC Stage III
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in…
- Trial name
- NCT07410975
- Testing
- sintilimab+IBI310+chemotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Endometrial Cancer, Endometrial Adenocarcinoma
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer.
- Trial name
- NCT05824481
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
An open-label multi-center phase II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 alone or in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04728321
- Testing
- AK104 lenvatinib, AK104
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Akeso
Metastatic Melanoma
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
- Trial name
- NCT03445533
- Testing
- Ipilimumab, Tilsotolimod with Ipilimumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 481 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Mesothelioma
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Background: Mesothelioma is a type of cancer. It originates in cells that line human body cavities. Most people have advanced disease when they are diagnosed. Researchers want to see if a combination of drugs can help.
- Trial name
- NCT04840615
- Testing
- LMB-100, ipilimumab, Diphenhydramine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
The NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell…
- Trial name
- NESCIO (NCT05148546)
- Testing
- Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 69 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Carcinoma in the Liver, Resectable Mass
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
This phase I trial studies the side effects and how well tremelimumab and durvalumab work in treating patients with colorectal cancer that has spread to the liver and can be removed by surgery.
- Conditions
- Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02754856
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Vulvar Cancer
AK104 for Recurrent or Metastatic Vulvar Cancer
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent…
- Trial name
- NCT05932212
- Testing
- AK104, AK104+ Paclitaxel+Cisplatin or Carboplatin
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Akeso
Healthy Male Volunteers
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects
- Trial name
- NCT06159101
- Testing
- HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group
- Where
- China
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV
Intrathecal Double Checkpoint Inhibition
The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small…
- Conditions
- Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV
- Trial name
- IT-IO (NCT05598853)
- Testing
- intrathecal nivolumab and intrathecal ipilimumab
- Where
- 3 sites in Switzerland
- Volunteers
- 26 people
- Sponsor
- University of Zurich
Advanced Cancer
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors
- Trial name
- NCT03203876
- Testing
- Lirilumab, Nivolumab, Ipilimumab
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer)
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Lung cancer is the leading cause of cancer-related deaths worldwide. According to the 2023 global cancer statistics, there are approximately 2.47 million new cases and 1.76 million deaths of lung cancer annually, accounting for…
- Trial name
- NCT07330596
- Testing
- QL1706 combined with Chemotherapy, Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Anhui Provincial Cancer Hospital
Cancer, Rare Disease
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
- Trial name
- NCT02938793
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Prisma Health-Upstate
Lung Cancer, Cancer
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified…
- Conditions
- Lung Cancer, Cancer, Immunotherapy, CAR-T Cell
- Trial name
- NCT03198052
- Testing
- CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University